- Investing Ideas
- /
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
51
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
51 companies
Sierra Oncology
Market Cap: US$1.3b
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs.
SRRA
US$54.99
7D
0.06%
1Y
179.4%
Arcturus Therapeutics Holdings
Market Cap: US$177.6m
Engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases.
ARCT
US$6.25
7D
1.5%
1Y
-67.2%
GeoVax Labs
Market Cap: US$6.1m
A clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
GOVX
US$0.21
7D
21.6%
1Y
-92.0%
Celcuity
Market Cap: US$4.7b
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
CELC
US$100.55
7D
-1.0%
1Y
663.5%
KalVista Pharmaceuticals
Market Cap: US$781.4m
A biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.
KALV
US$15.46
7D
1.9%
1Y
78.1%
Zai Lab
Market Cap: US$1.9b
A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
ZLAB
US$17.33
7D
-2.7%
1Y
-31.8%
Aprea Therapeutics
Market Cap: US$5.5m
A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
APRE
US$0.88
7D
-1.3%
1Y
-78.8%
Geron
Market Cap: US$842.6m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.32
7D
-1.5%
1Y
-61.2%
Dynavax Technologies
Market Cap: US$1.8b
A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally.
DVAX
US$15.38
7D
0.07%
1Y
20.5%
Heron Therapeutics
Market Cap: US$227.4m
A commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.
HRTX
US$1.24
7D
-8.1%
1Y
-26.6%
Immunocore Holdings
Market Cap: US$1.7b
A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
IMCR
US$33.78
7D
-4.5%
1Y
13.1%
Assembly Biosciences
Market Cap: US$511.1m
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
ASMB
US$32.31
7D
0.6%
1Y
86.0%
Mirum Pharmaceuticals
Market Cap: US$4.0b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$78.07
7D
-2.7%
1Y
81.2%
Akebia Therapeutics
Market Cap: US$411.3m
A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
AKBA
US$1.55
7D
-4.3%
1Y
-17.1%
Natera
Market Cap: US$31.7b
A diagnostics company, provides molecular testing services worldwide.
NTRA
US$228.84
7D
-1.1%
1Y
32.8%